BrainStorm Cell Therapeutics Inc. said Monday that the U.S. Food and Drug Administration will hold an Advisory Committee Meeting to discuss the company's Biologics License Application for NurOwn for the treatment of amyotrophic lateral sclerosis.

 

1) https://www.biospace.com/article/brainstorm-secures-fda-adcomm-for-als-therapy-nurown-

2) https://www.neurologylive.com/view/brainstorm-announces-fda-adcomm-meeting-nurown-stromal-cell-therapy

3) BrainStorm Cell Therapeutics Gets FDA Meeting to Review BLA for NurOwn

Dow Jones Newswires/MarketWatch, 3/27, By Chris Wack

https://www.marketwatch.com/story/brainstorm-cell-therapeutics-gets-fda-meeting-to-review-bla-for-nurown-d9fba62f